Methylene Blue

證據等級: L5

預測適應症: 3 個

Methylene Blue: Three TxGNN-Predicted Indications Evaluated

One-Sentence Summary

Methylene blue is not currently marketed in Taiwan (0 licenses on file), and its original indication and mechanism-of-action data are both gaps in this evidence pack. TxGNN predicts three possible new indications for this drug — Bronchitis, Methemoglobinemia (Alpha Type), and Methemoglobinemia due to Methemoglobin Reductase Deficiency — but the supporting evidence ranges from a likely false-positive prediction to an already well-established antidote mechanism.

Quick Overview

Item	Content
Original Indication	Not available (no original indications or Taiwan licenses on file)
US/Taiwan Market Status	Not Marketed
Number of NDAs	0

Predicted Indication	TxGNN Score	Evidence Level	Decision Stage	Recommended Decision
Bronchitis	99.97%	L5	S0	Hold
Methemoglobinemia, Alpha Type	99.36%	L3	S2	Proceed with Guardrails
Methemoglobinemia due to Methemoglobin Reductase Deficiency	99.36%	L4	S1	Research Question

Why Are These Predictions Reasonable (or Not)?

Detailed mechanism-of-action data for methylene blue is not available in this evidence pack (flagged as a High-severity data gap). Based on the literature retrieved for each candidate indication, the reasoning differs sharply by indication:

Bronchitis — The 10 literature hits retrieved are almost entirely unrelated to a therapeutic use of methylene blue in bronchitis. Most describe methylene blue as a diagnostic staining/dye reagent (fiberoptic bronchoscopy tumor staining, chromoendoscopy, bronchoalveolar lavage dilution marker, erythrocyte spectrophotometry) or are entirely unrelated compounds/drugs that merely mention “bronchitis” in passing. No study supports a treatment effect. This pattern is consistent with a knowledge-graph co-occurrence artifact — methylene blue’s frequent appearance alongside “bronchitis” in diagnostic-staining literature likely drove a spurious high TxGNN score rather than a genuine pharmacological signal.

Methemoglobinemia (Alpha Type) — This is mechanistically well-founded and not really a “new” indication: methylene blue is reduced by NADPH-dependent methemoglobin reductase to leucomethylene blue, which in turn reduces Fe³⁺ (methemoglobin) back to Fe²⁺ (functional hemoglobin). This is the classic antidote mechanism for acquired (drug/toxin-induced) methemoglobinemia and is already standard-of-care in many clinical guidelines — the TxGNN prediction here largely reconfirms known pharmacology.

Methemoglobinemia due to Methemoglobin Reductase Deficiency (hereditary/congenital form) — In patients with congenital cytochrome b5 reductase (diaphorase) deficiency, methylene blue can theoretically bypass the deficient enzyme via the same NADPH-dependent reduction pathway used in acquired methemoglobinemia. This extrapolation is mechanistically plausible but is currently supported only by case reports and veterinary (canine) data, not prospective human trials.

Clinical Trial Evidence

No registered clinical trials (ClinicalTrials.gov or ICTRP) were found for any of the three predicted indications.

Literature Evidence

1. Bronchitis

PMID	Year	Type	Journal	Key Findings
9387672	1996	Case Series (diagnostic staining)	Zhonghua wai ke za zhi	Methylene blue used as a bronchoscopic staining agent to distinguish malignant bronchial tumors from bronchitis; not a treatment study
7313968	1981	Case Series (diagnostic staining)	Terapevticheskii arkhiv	Chromoendoscopy with methylene blue for differential diagnosis of benign vs. malignant GI/bronchial lesions
31419501	2020	Preclinical (unrelated compound)	Journal of Ethnopharmacology	Essential oil of an unrelated plant (Lippia alnifolia) studied for tracheal relaxation; methylene blue not the study drug
29254574	2018	Analytical chemistry (unrelated)	Analytica Chimica Acta	Biosensor for theophylline detection; methylene blue not the study drug
21767626	2011	Preclinical (unrelated compound)	Journal of Ethnopharmacology	Antidepressant-like effects of an unrelated plant extract traditionally used for bronchitis; methylene blue not involved
8420409	1993	Methodological/Cohort	American Review of Respiratory Disease	Methylene blue used only as a dilution marker in bronchoalveolar lavage fluid quantitation
6121761	1982	Preclinical (unrelated drug)	Int J Clin Pharmacol Ther Toxicol	Methylene blue used only to measure circulation time in a beta-blocker cardiovascular study
20084922	2009	Case Report (unrelated)	Mikrobiyoloji Bulteni	Moraxella catarrhalis endocarditis case; bronchitis mentioned only as background pathogen context
17120034	2007	Case Report (unrelated)	European Journal of Pediatrics	Isolated tracheoesophageal fistula case; unrelated to methylene blue
2749902	1989	Basic science (unrelated)	Tsitologiia	Spectrophotometric study of erythrocyte methemoglobin using methylene blue-based reagent; unrelated to bronchitis

2. Methemoglobinemia, Alpha Type

PMID	Year	Type	Journal	Key Findings
3537620	1986	Review	Medical Toxicology	Clinical features and management review of drug/chemical-induced methemoglobinemia, including methylene blue’s role
26950891	2016	In vitro/Mechanistic	J Photochem Photobiol B	Photochemical/computational study of methylene blue-protein binding; notes known toxicities including methemoglobinemia

3. Methemoglobinemia due to Methemoglobin Reductase Deficiency

PMID	Year	Type	Journal	Key Findings
36638001	2023	Cohort (veterinary)	Am J Vet Res	Long-term oral methylene blue therapy in dogs with hereditary CYB5R-deficiency methemoglobinemia; effects on MetHb levels and inflammatory markers
35202847	2022	Case Report (veterinary)	Top Companion Anim Med	Oral methylene blue treatment in a dog with cytochrome b5 reductase deficiency
29845943	2018	Case Report	Netherlands J Medicine	61-year-old with congenital methemoglobinemia (CYB5R3 variant); methylene blue used diagnostically/therapeutically
14109019	1964	Case Report	Archives of Internal Medicine	Hereditary diaphorase deficiency and methemoglobinemia
14248326	1964	Case Report	Archives Françaises de Pédiatrie	Recessive congenital methemoglobinemia linked with diaphorase I deficiency

Market Information

Methylene blue is currently not marketed in Taiwan — 0 licenses on file, no dosage forms recorded.

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-drug interaction data are all currently unavailable — TFDA label data is flagged as a Blocking data gap (DG001), which prevents any S1 safety pre-assessment.)

Conclusion and Next Steps

1. Bronchitis — Decision: Hold

Rationale: The retrieved literature is almost entirely diagnostic-staining or unrelated-compound studies; no evidence supports a treatment effect. This is likely a knowledge-graph co-occurrence false positive.
To proceed: Would need genuine mechanistic or preclinical efficacy data in respiratory inflammation before any further evaluation — not recommended to pursue with current evidence.

2. Methemoglobinemia, Alpha Type — Decision: Proceed with Guardrails

Rationale: Mechanism (NADPH-dependent methemoglobin reductase pathway) is well established and already reflected in clinical management guidelines; evidence level L3 (review + mechanistic literature).
To proceed, the following is needed:
- TFDA package insert / label data (Blocking gap DG001) for dosing and contraindication confirmation
- Formal mechanism-of-action documentation (High gap DG002)
- Since the drug is not currently marketed in Taiwan, a market-entry or named-patient access pathway would need to be established

3. Methemoglobinemia due to Methemoglobin Reductase Deficiency — Decision: Research Question

Rationale: Mechanistically plausible extrapolation from the acquired-methemoglobinemia indication, but human evidence is limited to old case reports; the strongest recent data are veterinary (canine).
To proceed: Prospective case series or registry data in genetically confirmed CYB5R-deficient patients would be needed before moving beyond a research question.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.